Stock Ratings / Health Care / EVAX / forecast

CVM (39) GNTA (62) MGX (41) ALGS (26) ⌘ Pro Terminal →

Evaxion A/S (EVAX) 12-Month Stock Forecast & Price Target Cone

$3.08 -0.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.07

Evaxion A/S (EVAX) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $27.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.07 (-0.36%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVAX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY EVAX SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 43 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.07-7.8% Next Q

Q2 (-2Q)

Grade C-$2.83+32.9% Next Q

Q3 (-1Q)

Grade C$3.76-18.1% Next Q

Current

Grade D+$3.08+0% Hist 90D α

Trajectory: C- (50) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EVAX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, EVAX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.18) or 200D SMA ($3.50) invalidates the momentum regime and cuts Target Base ($3.08) toward Bear Floor ($2.40).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EVAX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your EVAX Position Size: $10,000

Shares at $3.08: 3246.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.40

$7,792

$-2,208 (-22.1%)

12M Consensus BaseTarget $3.08

$10,000

+$0 (+0.0%)

12M Bull Case BreakoutTarget $7.27

$23,604

+$13,604 (+136.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$7	69%	B
JP MorganUS Large-Cap Research	HOLD	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVAX)

✓Walkthrough of EVAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EVAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.16%📐 HORIZONTAL RANGE

2026-10-30O $3.11H $3.15L $2.89C $3.08VOL 46.2K

RES: $4.58SUP: $2.71SMA50: $3.18SMA200: $3.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVAX Butterfly Map → + Track EVAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EVAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EVAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVAX)

Health Care Rank #239 of 1016 ⚔️ CVM vs EVAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EVAX vs. CVM, GNTA, MGX, ALGS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Evaxion A/S (EVAX) ranks #239 by composite RQD confidence (58/100, grade D+) and #812 by equity capitalization ($27.8M). Within this direct 5-issuer industry benchmark cohort, EVAX leads on earnings valuation at N/A trailing P/E, while CVM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with EVAX at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EVAX ACTIVE Evaxion A/S	D+	58/100	—	—	—	-0.96%	$27.8M	Benchmark Subject
CVM Cel-Sci Corporation	D-	39/100	—	—	-35.0%	-6.25%	$26.4M	/cvm-vs-evax →
GNTA Genenta Science S.p.A.	C	62/100	—	—	—	+2.48%	$29.9M	/gnta-vs-evax →
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-evax →
ALGS Aligos Therapeutics Inc.	E	26/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-evax →

2. EVAX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Evaxion A/S (EVAX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $27.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. EVAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Evaxion A/S (NASDAQ: EVAX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $3.08 (-0.96% 1D, market cap $27.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVAX ranks #239 in composite RQD confidence.

How does EVAX compare to CVM and GNTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EVAX carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $26.4M) and GNTA (Genenta Science S.p.A.) posts a C grade (62/100 RQD, P/E N/A, ROIC —, cap $29.9M). Among the 5-stock peer group, EVAX leads on earnings multiple (N/A) while CVM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EVAX?

For Evaxion A/S (EVAX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #239 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EVAX trading relative to its 50-day, 200-day, and 52-week technical levels?

EVAX last traded at $3.08 (-0.96% on volume of 41,318 shares), positioning the stock -3.14% below its 50-day simple moving average ($3.18) and -12.00% below its 200-day simple moving average ($3.50). Across its 52-week range of $2.72 to $6.92, EVAX sits at the 8.6% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.69 to $3.47).

EVAX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EVAX's 12-month stock price target?

Evaxion A/S (EVAX) carries a 12-month consensus base price target of $3.08 (+0% from $3.08), with a bull-case target of $7.27 and a bear-case floor of $2.4.

Is EVAX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EVAX D+ (Sell — SELL) with an RQD Confidence score of 58/100.

Direct Sub-Reports: EVAX RQD Cockpit EVAX 12M Forecast EVAX Earnings & Move EVAX Dividends & DRIP EVAX Insiders & 13F EVAX Whale Options EVAX Profit Sankey EVAX News & Why